{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:35:19Z","timestamp":1761824119315,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00277-019-03640-y","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T07:02:56Z","timestamp":1554706976000},"page":"1689-1701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Multiple myeloma in elderly patients\u2014a Portuguese multicentric real-life study"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3978-766X","authenticated-orcid":false,"given":"Cristina","family":"Jo\u00e3o","sequence":"first","affiliation":[]},{"given":"Rui","family":"Bergantim","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Neves","sequence":"additional","affiliation":[]},{"given":"S\u00e9rgio","family":"Chacim","sequence":"additional","affiliation":[]},{"given":"Celina","family":"Afonso","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Barradas","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Bernardo","sequence":"additional","affiliation":[]},{"given":"Henrique","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"Gra\u00e7a","family":"Esteves","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Fraga","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Geraldes","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Jorge","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Macedo","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Mendon\u00e7a","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"Adriana","family":"Roque","sequence":"additional","affiliation":[]},{"given":"Ana Bela","family":"Sarmento","sequence":"additional","affiliation":[]},{"given":"Fernanda","family":"Trigo","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Vit\u00f3ria","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Esteves","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"L\u00facio","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"3640_CR1","unstructured":"(2017) National Cancer Institute SEER. In: National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER). 2017. \n                    http:\/\/www.seer.cancer.gov\n                    \n                  . Accessed 2017"},{"key":"3640_CR2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359\u2013E386. \n                    https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"key":"3640_CR3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (Oxford, England : 1990) 49:1374\u20131403. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2012.12.027","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"3640_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P (2017) Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia 31:1915\u20131921. \n                    https:\/\/doi.org\/10.1038\/leu.2016.380","journal-title":"Leukemia"},{"key":"3640_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","volume":"46","author":"M Schaapveld","year":"2010","unstructured":"Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E (2010) Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer (Oxford, England : 1990) 46:160\u2013169. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2009.07.006","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"3640_CR6","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","volume":"16","author":"D Pulte","year":"2011","unstructured":"Pulte D, Gondos A, Brenner H (2011) Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 16:1600\u20131603. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2011-0229","journal-title":"Oncologist"},{"key":"3640_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, Miguel JS, Sonneveld P, Palumbo A (2013) Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 98:980\u2013987. \n                    https:\/\/doi.org\/10.3324\/haematol.2012.075051","journal-title":"Haematologica"},{"key":"3640_CR8","doi-asserted-by":"publisher","first-page":"808","DOI":"10.6004\/jnccn.2014.0195","volume":"12","author":"K Anderson","year":"2014","unstructured":"Anderson K (2014) Multiple myeloma: advances reported in 2013 are useful in the clinic. J Natl Compr Cancer Netw 12:808\u2013811","journal-title":"J Natl Compr Cancer Netw"},{"key":"3640_CR9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/leu.2014.23","volume":"28","author":"SY Kristinsson","year":"2014","unstructured":"Kristinsson SY, Anderson WF, Landgren O (2014) Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 28:1346\u20131348. \n                    https:\/\/doi.org\/10.1038\/leu.2014.23","journal-title":"Leukemia"},{"key":"3640_CR10","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33:2863\u20132869. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"key":"3640_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart K, Rajkumar SV, Chanan-Khan A, Lacy MQ (2013) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic proceedings Mayo Clinic 88:360\u2013376. \n                    https:\/\/doi.org\/10.1016\/j.mayocp.2013.01.019","journal-title":"Mayo Clinic proceedings Mayo Clinic"},{"key":"3640_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3324\/haematol.2014.110296","volume":"99","author":"S Zweegman","year":"2014","unstructured":"Zweegman S, Palumbo A, Bringhen S, Sonneveld P (2014) Age and aging in blood disorders: multiple myeloma. Haematologica 99:1133\u20131137. \n                    https:\/\/doi.org\/10.3324\/haematol.2014.110296","journal-title":"Haematologica"},{"key":"3640_CR13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122\u20131128. \n                    https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"3640_CR14","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","volume":"126","author":"A Larocca","year":"2015","unstructured":"Larocca A, Palumbo A (2015) How I treat fragile myeloma patients. Blood 126:2179\u20132185. \n                    https:\/\/doi.org\/10.1182\/blood-2015-05-612960","journal-title":"Blood"},{"key":"3640_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clml.2016.12.002","volume":"17","author":"K Bergin","year":"2017","unstructured":"Bergin K, McQuilten Z, Moore E, Wood E, Spencer A (2017) Myeloma in the real world: what is really happening? Clin Lymphoma Myeloma Leuk 17:133\u2013144.e1. \n                    https:\/\/doi.org\/10.1016\/j.clml.2016.12.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3640_CR16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos M-V, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BGM, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125:2068\u20132074. \n                    https:\/\/doi.org\/10.1182\/blood-2014-12-615187","journal-title":"Blood"},{"key":"3640_CR17","doi-asserted-by":"crossref","unstructured":"Facon T, Hulin C, Dimopoulos MA, et al (2015) A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low-dose dexamethasone on the FIRST trial","DOI":"10.1182\/blood.V126.23.4239.4239"},{"key":"3640_CR18","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, Miguel JFS (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"3640_CR19","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1200\/EDBK_159009","volume":"35","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV (2016) Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book 35:e418\u2013ee23. \n                    https:\/\/doi.org\/10.14694\/EDBK_159009","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3640_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ajh.21904","volume":"86","author":"A Kumar","year":"2011","unstructured":"Kumar A, Hozo I, Wheatley K, Djulbegovic B (2011) Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol 86:18\u201324. \n                    https:\/\/doi.org\/10.1002\/ajh.21904","journal-title":"Am J Hematol"},{"key":"3640_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825\u2013831. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(06)68338-4","journal-title":"Lancet"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03640-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T23:22:16Z","timestamp":1586215336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03640-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3640"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03640-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"20 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CJ has received a research grant from Takeda and has received speaker honorarium\/participation in advisory boards from Celgene, Janssen, Takeda, and Amgen. MN received a speaker honorarium from Janssen, Takeda, Amgen, and Celgene. RB has received a research grant: from APCL\/SPH\/AMGEN and Celgene and speaker honoraria\/advisory board from Celgene, Janssen, Takeda, and Amgen. SC has received speaker honorarium or participation in Advisory Boards from Takeda, Janssen, Celgene, Sanofi, Bristol-Myers Squibb, and Abbvie. CG has received honoraria from Janssen, Celgene, Amgen, and Takeda for lectures and participation in advisory boards. JB declares that he has no conflict of interest. HV has received honoraria from Celgene and Amgen for participation in advisory boards. ABS declares that she has no conflict of interest. TM declares that she has no conflict of interest. AM declares that she has no conflict of interest. AR declares that she has no conflict of interest. SE declares that she has no conflict of interest. AM declares that she has no conflict of interest. FT has received honoraria for speaker services from Takeda, Amgen, Celgene, Janssen, and attendance at advisory boards for Takeda, Amgen, Celgene, and Janssen. HC declares that he has no conflict of interest. CG has received honoraria from Celgene, Amgen, and Janssen for participation in advisory boards. CF has received honoraria for speaker services, attendance at advisory boards, and travel reimbursement from Sanofi Genzyme. MB has received honoraria for speaker services from Janssen and attendance at advisory boards of Celgene, Amgen, Janssen, Takeda, and Merck. GE has received research grants and speaker honorarium from Celgene, Janssen, and Amgen. CA has received honorarium for participation in advisory boards from Amgen, Celgene, Janssen, and Takeda. AJ received a speaker honorarium from Celgene, Janssen, and Novartis. PL has received speaker honorarium\/participation in advisory boards from Celgene, Janssen, Takeda, and Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}